Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3257093 | 0.92 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| SCHEMBL2372630 | 0.90 | GPR119 (0.81) | GPR119CYP2C9KCNH2 | |
| SCHEMBL1712505 | 0.89 | GPR119 (1.00) | GPR119CYP2C9KCNH2 | |
| SCHEMBL5821469 | 0.89 | GPR119 (0.81) | GPR119CYP2C9KCNH2 | |
| SCHEMBL5133272 | 0.86 | GPR119 (0.60) | GPR119CYP2C9KCNH2 | |
| SCHEMBL1071583 | 0.82 | GPR119 (0.69) | GPR119CYP2C9KCNH2 | |
| SCHEMBL390024 | 0.81 | GPR119 (1.00) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12241590 | 0.81 | GPR119 (0.67) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12241593 | 0.81 | GPR119 (0.85) | GPR119CYP2C9KCNH2 | |
| SCHEMBL389831 | 0.80 | GPR119 (1.00) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | claimed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2049523-A1 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008005576-A1 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | GPR119, DPP4, GLP1R | GPR119 1/4885CYP2C9 2459/4885KCNH2 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.